Rangering i aksjer
#35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Aksjekurs
$0.594
Sist synkronisert: 2026-08-14
Handel Mustang Bio, Inc. (MBIO)
Pris MBIO pris med markedsverdi på B
Markedsverdi av Mustang Bio, Inc.(MBIO)
Markedsverdi: $4.50M
Per August 2026 har Mustang Bio, Inc. en markedsverdi på $4.50M. Dette gjør Mustang Bio, Inc. til det 35075th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Mustang Bio, Inc. fra 2017 til 2026
MBIO sammenlignet med topp 5 mest populære stocks
| Pris på MBIO |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+121,120,021.99%
|
|
|
|
|
$4.490T
|
+99,751,364.49%
|
|
|
|
|
$4.162T
|
+92,473,024.90%
|
|
|
|
|
$3.676T
|
+81,674,486.86%
|
|
|
|
|
$2.833T
|
+62,939,517.25%
|
